“Liquid liver biopsy” uses a single blood sample to measure individual NASH components

BOULDER, Colo., April 20, 2020 — SomaLogic announced today that it has added a new set of four research use only (RUO) SomaSignal™ tests that can diagnose all four components of non-alcoholic steatohepatitis (NASH) without the need for an invasive liver biopsy.

Fat build up in the liver affects approximately 100 million Americans and is one of the most common causes of liver disease in the US. NASH is marked by liver inflammation and damage that progresses silently and can lead to cirrhosis, liver cancer and liver failure. Early detection is key for disease management, but NASH diagnosis is currently made via liver biopsy, which is costly and potentially risky for patients. 

The SomaSignal™ NASH Bundle  provides information related to the same components seen in a liver biopsy — steatosis, lobular inflammation, hepatocellular ballooning and fibrosis — without the need for invasive tissue collection. SomaSignal™ tests measure specific proteins in a small blood sample and then use computer algorithms to provide health and wellness information. The new NASH Bundle tests can be used today to better understand the biology of NAFLD/NASH, including identifying new drug targets and drug effects.

SomaSignal™ NASH Bundle RUO tests are available to pharma and academic collaborators either alone or in conjunction with the full 5000 protein measurements derived from the SomaScan® Assay through SomaLogic’s SomaScan® Discovery Alliance.

All SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have not been cleared or approved by the US Food and Drug Administration.



SomaLogic Contact

Laura S. Mizoue, Ph.D.
Communications Specialist
T: 720-417-7509

About SomaLogic
SomaLogic seeks to deliver precise, meaningful, and actionable health-management information that empower individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s precise, proprietary, and personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.